See more : A2Z Infra Engineering Limited (A2ZINFRA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Evogene Ltd. (EVGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evogene Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Homes & Holiday AG (HHH.DE) Income Statement Analysis – Financial Results
- PC Connection, Inc. (CNXN) Income Statement Analysis – Financial Results
- SKY Network Television Limited (SKT.AX) Income Statement Analysis – Financial Results
- ShoulderUp Technology Acquisition Corp. (SUAC-WT) Income Statement Analysis – Financial Results
- Santen Pharmaceutical Co., Ltd. (4536.T) Income Statement Analysis – Financial Results
Evogene Ltd. (EVGN)
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.64M | 1.68M | 930.00K | 1.04M | 753.00K | 1.75M | 3.38M | 6.54M | 11.13M | 14.51M | 17.58M | 17.07M | 14.90M |
| Cost of Revenue | 4.24M | 909.00K | 767.00K | 574.00K | 334.00K | 1.45M | 2.85M | 5.64M | 8.26M | 9.71M | 10.11M | 9.55M | 8.25M |
| Gross Profit | 1.40M | 766.00K | 163.00K | 466.00K | 419.00K | 295.00K | 536.00K | 901.00K | 2.87M | 4.80M | 7.47M | 7.52M | 6.65M |
| Gross Profit Ratio | 24.80% | 45.73% | 17.53% | 44.81% | 55.64% | 16.89% | 15.85% | 13.78% | 25.82% | 33.09% | 42.47% | 44.05% | 44.65% |
| Research & Development | 18.11M | 20.79M | 23.86M | 19.96M | 17.82M | 16.77M | 18.67M | 18.10M | 16.41M | 15.87M | 12.62M | 7.25M | 6.38M |
| General & Administrative | 8.67M | 6.48M | 7.25M | 5.32M | 3.77M | 3.51M | 3.81M | 3.89M | 4.38M | 4.19M | 3.56M | 3.39M | 3.45M |
| Selling & Marketing | 1.01M | 3.93M | 653.00K | 520.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.68M | 10.42M | 7.25M | 5.32M | 3.77M | 3.51M | 3.81M | 3.89M | 4.38M | 4.19M | 3.56M | 3.39M | 3.45M |
| Other Expenses | 0.00 | -3.50M | 0.00 | 15.02M | -41.00K | -120.00K | -67.00K | -33.00K | 0.00 | -231.00K | -147.00K | -205.00K | -156.00K |
| Operating Expenses | 27.79M | 27.71M | 31.12M | 25.28M | 21.59M | 20.28M | 22.48M | 21.99M | 20.80M | 20.06M | 16.19M | 10.65M | 9.84M |
| Cost & Expenses | 32.03M | 28.62M | 31.88M | 25.85M | 21.92M | 21.74M | 25.33M | 27.63M | 29.05M | 29.77M | 26.30M | 20.20M | 18.08M |
| Interest Income | 1.25M | 516.00K | 1.94M | 1.59M | 2.46M | 1.41M | 2.13M | 2.42M | 2.57M | 2.24M | 1.18M | 869.00K | 383.00K |
| Interest Expense | 171.00K | 3.33M | 1.41M | 2.95M | 386.00K | 2.21M | 1.01M | 891.00K | 1.86M | 1.52M | 1.34M | 89.00K | 7.00K |
| Depreciation & Amortization | 2.61M | 2.58M | 2.23M | 2.73M | 2.77M | 2.02M | 2.15M | 2.28M | 2.43M | 2.25M | 2.04M | 1.84M | 1.42M |
| EBITDA | -23.20M | -26.93M | -27.80M | -23.18M | -15.97M | -18.62M | -18.55M | -18.81M | -15.49M | -13.01M | -7.20M | -1.29M | -1.76M |
| EBITDA Ratio | -411.42% | -1,423.58% | -2,880.00% | -1,970.77% | -2,116.33% | -947.68% | -522.83% | -285.40% | -137.93% | -89.68% | -42.90% | -8.17% | -36.05% |
| Operating Income | -26.39M | -26.94M | -30.95M | -24.81M | -21.17M | -19.99M | -21.95M | -21.09M | -17.92M | -15.26M | -8.72M | -3.13M | -3.18M |
| Operating Income Ratio | -467.93% | -1,608.42% | -3,328.28% | -2,385.96% | -2,810.89% | -1,144.19% | -649.13% | -322.46% | -161.03% | -105.13% | -49.60% | -18.31% | -21.36% |
| Total Other Income/Expenses | 404.00K | 687.00K | 521.00K | -1.36M | 2.08M | -793.00K | -1.73M | 1.53M | 708.00K | 726.00K | -157.00K | 678.00K | 3.83M |
| Income Before Tax | -25.99M | -29.75M | -30.43M | -26.17M | -19.09M | -20.78M | -20.83M | -19.56M | -17.21M | -14.53M | -8.88M | -2.45M | 645.00K |
| Income Before Tax Ratio | -460.76% | -1,776.36% | -3,272.26% | -2,516.73% | -2,535.33% | -1,189.58% | -616.00% | -299.02% | -154.67% | -100.13% | -50.50% | -14.34% | 4.33% |
| Income Tax Expense | -33.00K | 90.00K | 13.00K | 32.00K | 24.00K | 30.00K | 11.00K | 36.00K | -2.20M | -1.80M | -1.67M | 74.00K | -3.83M |
| Net Income | -23.88M | -26.64M | -27.79M | -23.37M | -18.11M | -20.76M | -20.84M | -19.59M | -17.21M | -14.53M | -8.88M | -2.52M | 645.00K |
| Net Income Ratio | -423.39% | -1,590.33% | -2,988.49% | -2,247.50% | -2,405.31% | -1,188.21% | -616.33% | -299.57% | -154.67% | -100.13% | -50.50% | -14.77% | 4.33% |
| EPS | -5.23 | -6.46 | -6.87 | -8.30 | -0.70 | -0.81 | -0.81 | -0.77 | -0.68 | -0.58 | -0.45 | -0.14 | 0.04 |
| EPS Diluted | -5.23 | -6.46 | -6.87 | -8.30 | -0.70 | -0.81 | -0.81 | -0.77 | -0.68 | -0.58 | -0.45 | -0.14 | 0.03 |
| Weighted Avg Shares Out | 4.57M | 4.12M | 4.04M | 2.82M | 25.75M | 25.75M | 25.73M | 25.44M | 25.31M | 25.05M | 19.73M | 18.42M | 17.51M |
| Weighted Avg Shares Out (Dil) | 4.57M | 4.12M | 4.04M | 2.82M | 25.75M | 25.75M | 25.73M | 25.44M | 25.31M | 25.05M | 19.73M | 18.42M | 18.73M |
EverGen Infrastructure Corp. Announces Change of Auditors
Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
Evogene Ltd. (EVGN) Q2 2024 Earnings Call Transcript
EVGN Stock Earnings: Evogene Misses EPS, Beats Revenue for Q2 2024
Evogene Reports Second Quarter 2024 Financial Results
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Evogene Schedules Second Quarter 2024 Financial Results Release
Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Source: https://incomestatements.info
Category: Stock Reports